Heparin-induced thrombocytopenia. Thrombocytopenia, unspecified
Conditions
Interventions
Intervention group: In patients admitted to the internal ward of Rasool Akram Hospital who are diagnosed with HIT by the 4T Score, heparin will be discontinued and apixaban will be started. Based on
so we will use mentioned dose in the treatment of DVT or PE and in the prevention of stroke in non-valvular ?AF. In prophylactic setting, we will use a dose of 2.5 mg twice a day, unless the patient e
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Age 18 years or older 2) HIT detection based on 4T Score equal to or above 4
Exclusion criteria
Exclusion criteria: Patients with active bleeding Patient with inherited or acquired coagulation disease or bleeding disorder Patients receiving cytochrome P-450 3A4 inhibitors or inducers Severe renal failure (CrCl <25 ml / min) Severe liver disease (including Child-Pugh B and C) The patient needs surgery History of uncorrected cerebral aneurysm, intracranial tumor or vascular accident Non-participation in research projects during the 30 days prior to the study Pregnant and lactating women Previous treatment with a non-heparin anticoagulant Covid-19 infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Follow-up of arterial / venous thrombosis after receiving apixaban. Timepoint: If the patient becomes symptomatic. Method of measurement: Doppler ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality rate. Timepoint: Daily. Method of measurement: Loss of vital signs and death of the patient.;Bleeding event following the use of apixaban. Timepoint: Daily. Method of measurement: Based on the patient's symptoms such as petechiae. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Farasatinasab
Iran University of Medical Sciences
Outcome results
None listed